Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07292688
PHASE1

Study of CM383 in Healthy Subjects

Sponsor: Keymed Biosciences Co.Ltd

View on ClinicalTrials.gov

Summary

This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.

Official title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CM383 Following Intravenous and Subcutaneous Administration in Healthy Adult Subjects

Key Details

Gender

MALE

Age Range

18 Years - 54 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-01

Completion Date

2026-07

Last Updated

2026-01-23

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

CM383

CM383 subcutaneous injection, once.

BIOLOGICAL

CM383

CM383 intravenous infusion, once.

Locations (1)

The Second Affiliated Hospital Zhejiang University School of Medcine

Hangzhou, China